On June 29, 2006, Cornell University and Stanford University researchers reported that a meta-analysis they conducted found that "regularly inhaled beta-agonists (Orciprenaline/metaproterenol formoterol Foradil, fluticasone/salmeterol [Serevent, Advair, and salbutamol/albuterol Ventolin, Volmax, and others) increased the risk of respiratory death more than twofold, compared with a placebo," while used to treat chronic obstructive pulmonary disease (COPD).